- Major tech companies like Microsoft, Google, Amazon, and OpenAI are heavily investing in and competing within the AI revolution.
- Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
- AI stocks are benefiting from the trend of onshoring and tariffs implemented during the Trump era.
- Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.
Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
7 reports, 2 independent
Updated Jul 9
Gone quiet
- Reports
- 7
- Developments
- 7
- Repetition
- 14%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approves Afrezza and grants Breakthrough designation to MannKind amidst tariff benefits for AI stocks.1 source
- Trump tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.Sub-event
AI stocks benefit from tariffs, coupled with a company acquisition and FDA breakthrough designation.1 source
Specific company receives FDA IND approval amidst AI stock benefits from tariffs.1 source
Iovance Biotherapeutics benefits from Trump-era tariffs and onshoring trend.1 source
- ImmunityBio is cited as benefiting from Trump tariffs and FDA approvals.
- Akebia Therapeutics is cited as a beneficiary of Trump-era tariffs and onshoring trends.
Keep exploring
Part of
Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.Also in this story
- BP-205 pipeline offers future growth potential, and WAKIX revenue drives company financial performance.
- Trump-era tariffs benefit certain AI stocks, and Aptevo Therapeutics regained compliance with Nasdaq listing rules.
- MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.
- Wells Fargo raised its price target on Teneable Holdings, citing benefits from Trump-era tariffs and onshoring trends.
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
ImmunityBio
biotech company
Nothing else this week.
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
Related events
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
- Tariffs and onshoring trends may benefit AI stocks, with energy infrastructure like Kinder Morgan noting that they transport 40% of the natural gas produced in the US.
Coverage
Newest first; wire copies grouped- yahoo.com
- Insider MonkeyBausch Health Companies Inc. (BHC) Expands Hepatology Portfolio with DURECT Acquisition We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Bausch Health Companies Inc. i
- Insider MonkeyRadiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01) Radiopharm Theranostics Limited (NASDAQ:RADX)
- Insider MonkeyIovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the penny stocks that will skyrocket. On July 15, Ci
- Insider MonkeyImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best American Penny Stocks to Buy According to Analysts. On
- Unknown outlet
- Unknown outlet